{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"The first three months of therapy will be used as the time period in which toxicity will be evaluated and stopping rules for unacceptable toxicity will be implemented. Rules for stopping the study will be based on the rate of withdrawal due to significant toxicity (grade IV, non-hematological, non-metabolic, nonperipheral neuropathy).","groups":[{"description":"Patients receive bortezomib IV on days 2 and 5 and vorinostat PO QD on days 1-14. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.\n\nBortezomib: Given IV\n\nVorinostat: Given PO","id":"OG000","title":"Arm I (Bortezomib and Vorinostat)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"No patients met stopping rules for significant toxicity in the first three months of therapy.","reportingStatus":"POSTED","timeFrame":"The first three months of therapy","title":"Toxicity as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0","type":"PRIMARY","unitOfMeasure":"Participants"}